Medical treatment of epithelial ovarian cancer

References

• Jemal A, Tiwari RC, Murray T et aL Cancer statistics 2004. CA Cancerj Clin. 54,8–29 (2004).
   PubMed Web of Science ®Google Scholar
• Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Results of a National Ovarian Cancer Survey. Cancer89, 2068–2075 (2000).
   Google Scholar
• Ahmed FY, Wllshaw E, A'Hern RP et al. Natural history and prognosis of untreated Stage I epithelial ovarian carcinoma. J Clin. OncoL 14,2968–2975 (1996).
   Google Scholar
• Vergote I, De Brabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in Stage I invasive epithelial ovarian cancer. Lancet 357,176–182 (2001).
   PubMed Web of Science ®Google Scholar
• •• Defines the most important clinical prognostic factors in early stage ovarian cancer.
   Google Scholar
• Trope C, Kaern J, Hogberg T et al. Randomized study on adjuvant chemotherapy in Stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann. OncoL 11, 282–288 (2000).
   Google Scholar
• Bolis G, Colombo N, Pecorelli S et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann. OncoL 6,887–893 (1995).
   Google Scholar
• Young RC, Brady MF, Nieberg RM et al. Adjuvant treatment for early ovarian cancer: a randomized Phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin - a Gynecology Oncology Group Study. J Clin. OncoL 21,4350–4355 (2003).
   Google Scholar
• Bell J, Brady M, Lage J et al. A randomized Phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a Gynecologic Oncology Group Study. CynecoL OncoL 88,156 (2003).
   Google Scholar
• Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early stage ovarian carcinoma: European Organization for Research and Treatment of Ovarian Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Nat] Cancer Inst. 95, 113–125 (2003).
   PubMed Web of Science ®Google Scholar
• International Collaborative Ovarian Neoplasm Trial 1. Randomized trial of adjuvant chemotherapy in women with early stage ovarian cancer. J Nall Cancer Inst. 95,125-132 (2003).
   Google Scholar
• Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm Trial: two parallel randomized Phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Nat] Cancer Inst. 95, 105–112 (2003).
   PubMed Web of Science ®Google Scholar
• ••Confirmed the role of adjuvant platinum-based chemotherapy.
   Google Scholar
• Young RC, Walton LA, Ellenberg SS et al. Adjuvant therapy in Stage I and II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl. J Med. 322, 1021–1027 (1990).
   PubMed Web of Science ®Google Scholar
• Vergote IB, Vergote-De Vos LN, Abeler VM et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 69,741–749 (1992).
   PubMed Web of Science ®Google Scholar
• Hoskins WI Bundy BN, Thigpen JT et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. CynecoL OncoL 47,159–166 (1992).
   PubMedGoogle Scholar
• Hoskins WI McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. j Obst. CynecoL 170,974–980 (1994).
   PubMedGoogle Scholar
• Allen DG, Heintz AE Touw FVV. A meta-analysis of residual disease and survival in Stage III and IV carcinoma of the ovary. Ear. j Cynaecol. Oncol. 16, 349–356 (1995).
   PubMedGoogle Scholar
• Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: a meta-analysis. J Cilia. OncoL 20, 1248–1259 (2002).
   PubMed Web of Science ®Google Scholar
• •Meta-analysis showing survival benefit of cytoreduction for advanced ovarian carcinoma.
   Google Scholar
• Junor EJ, Hole DJ, McNulty L et al. Specialist gynaecologist and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br. J Obstet. CynaecoL 106,1130–1136 (1999).
   Google Scholar
• Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patients from 37 randomized trials. Br. J Cancer 78, 1479–1487 (1998).
   Google Scholar
• McGuire WP, Hoskins WI Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and IV ovarian cancer. N Engl. Med. 334,1–6 (1996).
   Google Scholar
• ••Established the combination of taxane anda platinum agent as the standard therapy in advanced ovarian carcinoma.
   Google Scholar
• Piccart M, Bertelsen K, James K et al. Randomized Intergroup trial of cisplatin—paclitaxel vs. cisplatin—cyclophosphamide in women with advanced epithelial ovarian cancer: 3 years results. J Nat] Cancer Inst. 92, 699–708 (2000).
   Google Scholar
• •Confirmed the combination of platinum and taxane as standard.
   Google Scholar
• Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin vs. paclitaxel vs. cisplatin and paclitaxel in patients with suboptimal Stage III or IV ovarian cancer. A GOG study. J OncoL 18,106–115 (2000).
   Google Scholar
• •Suggests that the outcome with sequential platinum—taxane administration can be similar to that of concurrent administration.
   Google Scholar
• Sandercock J, Parmar MKB, Torn i V. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br. J Cancer 78, 1471–1478 (1998).
   Google Scholar
• The ICON collaborators. ICON2: randomised trial of single agent carboplatin against three drug combination of CAP (cyclophosphamide—doxorubicin and cisplatin) in women with ovarian cancer. Lancet352, 1571–1576 (1998).
   PubMedGoogle Scholar
• The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360, 505–515 (2002).
   Google Scholar
• •Instigated the controversy of carboplatin monotherapy versus paclitaxel—platinum combination in first-line therapy.
   Google Scholar
• Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J OncoL 18,3084–3092 (2000).
   Google Scholar
• du Bois A, Dick H-J, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Nat] Cancer Inst. 95, 1320–1330 (2003).
   PubMedGoogle Scholar
• Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study.Oncol. 21, 3194–3200 (2003).
   Google Scholar
• •Demonstrated paclitaxel—carboplatin to be as effective as paclitaxel—cisplatin in optimally debulked advanced ovarian carcinoma.
   Google Scholar
• Covens A, Carey M, Bryson P et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with Stage II, III, or IV epithelial ovarian cancer. Gynecol. Oncol. 85, 71–80 (2002).
   PubMed Web of Science ®Google Scholar
• Gore M. Carboplatin equals cisplatin: but how do I prescribe it?./. Cilia. Oncol. 17, 3183–3185 (2003).
   Google Scholar
• Vasey P Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin vs. paclitaxel—carboplatin in epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 21, 202a (2002) (Abstract 804).
   Google Scholar
• Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for Stage III ovarian cancer. N Engl. j Med. 335, 1950–1955 (1996).
   PubMed Web of Science ®Google Scholar
• Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume Stage III ovarian carcinoma: an Intergroup Study of the GOG, SWOG and ECOG.Oncol. 19, 1001–1007 (2001).
   Google Scholar
• Armstrong DK, Bundy BN, Baergen R et al. Randomized Phase III study of intravenous paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal cisplatin and IP paclitaxel in optimal Stage III epithelial ovarian cancer: a Gynecologic Oncology Group trial (GOG 172). Proc. Am. Soc. Clin. One& 21, 201a (2002) (Abstract 803).
   Google Scholar
• Alberts D, Markman M, Armstrong D et al. Intraperitoneal therapy for Stage III ovarian cancer: a therapy whose time has come Clin. One& 20, 3944–3946 (2002).
   Google Scholar
• Gonzalez Martin A, Lopez Garcia M, Garcia Martinez H et al. Futuras lineas de investigación en cancer de ovario. Rev. Oncologia 15(5), 28–36 (2001).
   Google Scholar
• Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. j Cilia. Oncol. 21, 2460–2465 (2003).
   Google Scholar
• •Demonstrated the potential benefit of prolonged chemotherapy following complete response, and established the basis for future consolidation studies.
   Google Scholar
• Cure H, Battista C, Guastalla J et al. Phase III randomized trial of high-dose chemotherapy and peripheral blood stem cell support as consolidation in patients with advanced ovarian cancer: 5-year follow-up of a GINECO/FNCLCC/ SFGM-TC study. Proc. Am. Soc. Clin. Oncol. 23 (2004) (Abstract 5006).
   Google Scholar
• Markman M, Rothman R, Hakes T et al. Second line platinum therapy in patients with ovarian cancer previously treated with cisplatin.j Cilia. Oncol. 9,389–393 (1991).
   PubMed Web of Science ®Google Scholar
• Thipgen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71, 1559–1564 (1993).
   Google Scholar
• Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. j Cilia. Oncol. 10, 513–514 (1992).
   PubMed Web of Science ®Google Scholar
• Sabbatini E Spriggs D. Salvage therapy for ovarian cancer. Oncology12, 833–851 (1998).
   Google Scholar
• Advanced epithelial ovarian cancer: 1998 consensus statements. Ann. Oncol. 10 (1), S87—S92 (1999).
   Google Scholar
• Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 8, 963–968 (1997).
   Google Scholar
• Cantn MG, Buda A, Parma G et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. j Cilia. Oncol. 20, 1232–1237 (2002).
   PubMedGoogle Scholar
• Bolis G, Scarfone G, Villa A et al. Carboplatin alone vs. carboplatin plus epidoxorrubicin as second-line therapy for cisplatin or carboplatin-sensitive ovarian cancer. Gynecol. Oncol. 91, 3–9 (2001).
   Google Scholar
• Markman M. Single agent carboplatin is the treatment of choice in recurrent, potentially platinum-sensitive ovarian cancer. Am. Soc. Clin. One& Education Book, 38th Annual Meeting 521–523 (2002).
   Google Scholar
• Guastalla JP, Pujade-Lauraine E, Weber H et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO Phase II study. Ann. Oncol. 9, 37–43 (1998).
   Google Scholar
• Rose P, Fusco N, Fluellen L et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.Oncol. 16,1494–1497 (1998).
   Google Scholar
• Gronlund B, Hogdall C, Hansen HH et al. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol. 83, 128–134 (2001).
   PubMed Web of Science ®Google Scholar
• Dizon D, Hensley M, Sabbatini P et al. Carboplatin and paclitaxel as initial second line therapy in recurrent epithelial ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 20, 203a (2001) (Abstract 809).
   Google Scholar
• Bolis G, Scarfone G, Csiatta C et al. A Phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol. 83, 477–480 (2001).
   PubMed Web of Science ®Google Scholar
• Du Bois A, Luck HJ, Pfisterer J et al. Second line carboplatin and gemcitabine in platinum sensitive ovarian cancer: a dose finding study by the AGO Ovarian Cancer Study Group. Ann. Oncol. 12, 1115–1120 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrero J, Weber B, Lepille D et al. Caelyx and carboplatin in patients with advanced ovarian cancer in late relapse (>6 months): late results a GINECO Phase II trial. Proc. Am. Soc. Clin. Oncol. 23, 453 (2004) (Abstract 5022).
   Google Scholar
• Viens P, Bougnoux P, Dieras V et al. A Phase II trial of oxaliplatin and paclitaxel combination in advanced ovarian cancer patients pretreated with cisplatin or carboplatin + taxanes: preliminary results. Proc. A177. Soc. Clin. Oncol. 21, 223a (2002) (Abstract 889).
   Google Scholar
• The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet361, 2099-106 (2003).
   Google Scholar
• ••Demonstrated survival benefit for thepaclitaxel—platinum combination in platinum-sensitive relapsed ovarian carcinoma.
   Google Scholar
• Gonzalez-Martin A, Calvo E, Boyer I et al. Randomised Phase II study of carboplatin versus paclitaxel—carboplatin in platinum-sensitive recurrent advanced ovarian cancer: a GEICO study. Proc. Am. Soc. Clin. Oncol. 22, 451 (2003) (Abstract 1812).
   Google Scholar
• Pfisterer J, Plante M, Vergote I et al. Gemcitabineicarboplatin vs. carboplatin in platinum sensitive recurrent ovarian cancer. Results of a Gynecologic Cancer Intergroup randomized Phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Proc. Am. Soc. Clin. Oncol. 23,449 (2004) (Abstract 5005).
   Google Scholar
• McGuire W. Management of the patient with recurrent ovarian cancer. Am. Soc. Clin. Oncol. Education Book, 38th Annual Meeting 530–532 (2002).
   Google Scholar
• Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. JOncol. 13, 1584–1588 (1995).
   Google Scholar
• Mc Guire WP, Blessing JA, Bookman MA et al. Topotecan has substantial antitumor activity as first line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Cilia. Oncol. 18, 1062–1067 (2000).
   PubMedGoogle Scholar
• Rose PG, Blessing JA, Mayer AR et al. Prolonged oral etoposide as second line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin. Oncol. 16,405–410 (1998).
   PubMed Web of Science ®Google Scholar
• Vermorken J, Gore M, Perren T et al. Multicenter randomised Phase II study of oxaliplatin or topotecan in platinum-pretreated epithelial ovarian cancer patients. Proc. Am. Soc. Clin. Oncol. 20, 212a (2001) (Abstract 847).
   Google Scholar
• Ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Gum. Oncol. 15, 2183–2193 (1997).
   Google Scholar
• Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: arandomised Phase III study of pegylatedliposomal doxorubicin versus topotecan.Clin. Oncol. 19,3312–3322 (2001).
   Web of Science ®Google Scholar
• Kaye SB. Chemotherapy for recurrent ovarian cancer. Lancet 361,2094–2095 (2003).
   PubMedGoogle Scholar
• Gore M. Treatment of relapsed epithelial ovarian cancer. Am. Soc. Clin. Oncol. Education Book 468–476 (2001).
   Google Scholar
• Markman M, Hall J, Spitz D et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel- refractory ovarian cancer. JOncol. 20,2365–2369 (2002).
   Google Scholar
• Piccart M, Green J, Lacave A et al. Oxaliplatin or paclitaxel in patients with platinum pretreated advanced ovarian cancer: a randomised Phase II study of the EORTC of Cancer Gynecology Group. J Clin. Oncol. 18,1193–1202 (2000).
   PubMed Web of Science ®Google Scholar
• Vermorken J, Gore M, Perren T et al. Multicenter Randomized Phase II study of oxaliplatin or topotecan in platinum-pretreated epithelial ovarian cancer patients. Proc. Am. Soc. Clin. Oncol. 20, 212a (2001) (Abstract 847).
   Google Scholar
• Rosenberg P, Anderson H, Boman K et al. A randomised multicenter study of single agent paclitaxel given weekly versus every three weeks to patients with ovarian cancer previously treated with platinum therapy. Proc. Am. Soc. Clin. Oncol. 18,368a (1999) (Abstract 1420).
   Google Scholar